Aimmune Therapeutics, Inc. short interest in 2018
In 2018, Aimmune Therapeutics, Inc.'s disclosed short interest ran from 5.15% of shares outstanding on 12 Jan 2018 to 11.31% on 31 Dec 2018, a change of +6.16 percentage points. The year's high was 11.31% on 31 Dec 2018 and its low 5.04% on 15 Feb 2018, averaging 8.78% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 21.44 days on 13 Jul 2018. Full history: Aimmune Therapeutics, Inc..
Cite this page
2018 in figures
- Start of year
- 5.15% (12 Jan 2018)
- End of year
- 11.31% (31 Dec 2018)
- Change
- +6.16 pp
- High
- 11.31% (31 Dec 2018)
- Low
- 5.04% (15 Feb 2018)
- Average
- 8.78%
- Highest days to cover
- 21.44 (13 Jul 2018)
- SEC filings marked
- 8
Every report in 2018
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2018 | 5.15% | 6.68 | |
| 31 Jan 2018 | 5.10% | 5.75 | |
| 15 Feb 2018 | 5.04% | 5.63 | |
| 28 Feb 2018 | 7.51% | 1.24 | 10-K filed |
| 15 Mar 2018 | 8.13% | 3.37 | results (8-K) |
| 29 Mar 2018 | 9.12% | 4.68 | |
| 13 Apr 2018 | 8.82% | 5.96 | |
| 30 Apr 2018 | 8.45% | 11.98 | |
| 15 May 2018 | 8.79% | 10.71 | 10-Q filed, results (8-K) |
| 31 May 2018 | 8.67% | 10.57 | |
| 15 Jun 2018 | 8.93% | 9.26 | |
| 29 Jun 2018 | 10.18% | 7.94 | |
| 13 Jul 2018 | 10.13% | 21.44 | |
| 31 Jul 2018 | 9.88% | 17.41 | |
| 15 Aug 2018 | 9.48% | 17.03 | 10-Q filed, results (8-K) |
| 31 Aug 2018 | 9.05% | 16.17 | |
| 14 Sep 2018 | 9.65% | 10.61 | |
| 28 Sep 2018 | 8.62% | 9.71 | |
| 15 Oct 2018 | 9.43% | 13.10 | |
| 31 Oct 2018 | 9.82% | 14.17 | |
| 15 Nov 2018 | 9.60% | 6.37 | 10-Q filed, results (8-K) |
| 30 Nov 2018 | 10.12% | 6.88 | |
| 14 Dec 2018 | 9.84% | 9.45 | |
| 31 Dec 2018 | 11.31% | 6.19 |
See also: Aimmune Therapeutics, Inc.'s full history · most shorted US stocks of 2018 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.